SCHEMBL1260656

SCHEMBL1260656

C=CCCN1C(=O)Cc2cc(Cl)ccc2C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.45
MEN1 O00255 5/20 0.45
CASP6 P55212 2/20 0.45
METAP1 P53582 1/20 0.43
GAA P10253 4/20 0.41
APAF1 O14727 3/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 3/20 0.41
CASP1 P29466 1/20 0.41
RAB9A P51151 1/20 0.41
BLM P54132 1/20 0.41
CASP7 P55210 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HPGD P15428 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.39
USP2 O75604 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
SRD5A1 P18405 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1074709 0.81 KMT2A (0.48) KMT2AMEN1METAP1GAAAPAF1
SCHEMBL1020354 0.80 KMT2A (0.62) KMT2AMEN1CASP6GAAAPAF1
SCHEMBL1260713 0.78 USP2 (0.44) KMT2AMEN1CASP6GAAAPAF1
SCHEMBL8566878 0.75 KMT2A (0.71) KMT2AMEN1CASP6GAAAPAF1
SCHEMBL9918982 0.73 SRD5A1 (0.50) KMT2AMEN1CASP6METAP1GAA
SCHEMBL8432181 0.71 KMT2A (0.58) KMT2AMEN1CASP6GAAAPAF1
SCHEMBL8077147 0.70 KMT2A (0.57) KMT2AMEN1CASP6GAAAPAF1
SCHEMBL4725575 0.67 CASP3 (0.56) KMT2AMEN1ALDH1A1CASP3POLB
SCHEMBL29419302 0.66 CASP3 (0.58) ALDH1A1MAPTRAB9ACASP3SENP8
SCHEMBL3750109 0.66 KMT2A (0.79) KMT2AMEN1CASP6GAAAPAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461107-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2013-06-11 US disclosed
US-8461107-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2013-06-11 US disclosed
US-8461107-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2013-06-11 US disclosed
US-20110046161-A1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2011-02-24 US disclosed
US-20110046161-A1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2011-02-24 US disclosed
US-20110046161-A1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2011-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046161-A1 HCV NS3 PROTEASE INHIBITORS HAVCR2, GTF3C3, CTSC KMT2A 3629/4885MEN1 4761/4885CASP6 352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.